According to a pooled analysis of the PLAN B and SUCCESS C trials, anthracycline regimens provide no additional benefit and more adverse events when it comes to HER2−, high-risk breast cancer, compared to docetaxel/cyclophosphamide regimens. The gene discussed is ERBB2; the disease is breast carcinoma.